Monoclonal antibodies first garnered public attention early last October, when as part of his treatment, President Trump received what was then still an experimental drug. It received a share of the credit for his rapid recovery. In November, the FDA issued emergency use authorization to versions of MAB developed by Eli Lilly and Regeneron, for the purpose of stopping early, mild to moderate cases of COVID-19 before symptoms worsened. Among the parameters to qualify, patients must be treated within ten days of the onset of symptoms, and considered to be at risk of severe disease. Last month, ...